Article Details
Retrieved on: 2024-05-09 20:37:03
Tags for this article:
Click the tags to see associated articles and topics
Summary
Telesis Bio Inc., an American biopharma company in San Diego, reported lower Q1 2024 revenue but is focusing on its Gibson SOLA and BioXp mRNA solutions for DNA and mRNA drug discovery, with a significant collaboration with Pfizer. The financial summary reflects reduced operating expenses and a net loss decrease.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here